US 12,303,549 B2
Methods of treating or inhibiting onset of Huntington's disease
Steven A. Goldman, Webster, NY (US); and Mikhail Osipovitch, Frederiksberg (DK)
Assigned to University of Rochester, Rochester, NY (US); and University of Copenhagen, Copenhagen K (DK)
Appl. No. 17/254,734
Filed by University of Rochester, Rochester, NY (US); and University of Copenhagen, Copenhagen (DK)
PCT Filed Jun. 19, 2019, PCT No. PCT/US2019/037987
§ 371(c)(1), (2) Date Dec. 21, 2020,
PCT Pub. No. WO2019/246262, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/688,174, filed on Jun. 21, 2018.
Prior Publication US 2022/0062378 A1, Mar. 3, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 35/30 (2015.01); A61P 25/28 (2006.01)
CPC A61K 38/1709 (2013.01) [A61K 35/30 (2013.01); A61P 25/28 (2018.01)] 19 Claims
 
1. A method of treating or inhibiting onset of Huntington's disease, said method comprising:
selecting a subject having or at risk of having hypomyelination; and
administering to the selected subject one or more modulators of a gene or protein encoded thereof involved in the NKX2.2→OLIG2→SOX10→MYRF regulatory cascade, wherein the method results in an increase in myelination in the subject.